tbuckley/cabot-search huggingface dataset:
Long-term follow up of AIDS-related primary central nervous system lymphoma in the cART era.
Authors: Keiji Sugiyama, Yuki Kojima, Hirokazu Nagai, Takashi Odawara, Mihoko Yotsumoto, Atsushi Ajisawa, Shotaro Hagiwara, Tomoko Uehira, Toshikazu Miyakawa, Hidetoshi Igari, Soichirou Takahama, Hideta Nakamura, Seiji Okada
Journal: Journal of Clinical Oncology (2015)

e19504 Background: Primary central nervous system lymphoma (PCNSL) is one of the life-threatening diseases in patients (pts) with acquired immunodeficiency syndrome (AIDS). We previously reported the clinical outcomes of AIDS-related PCNSL with an estimated 3-year overall survival (OS) rate of 64% in the combination anti-retroviral therapy (cART) era. To clarify the long-term outcomes, we updated our data. Methods: This retrospective cohort study was performed in 2009 to examine the clinical outcomes of pts diagnosed with AIDS-related PCNSL who visited 12 regional hospitals for HIV/AIDS in Japan during 2002–2008. To investigate the long-term outcomes, the latest clinical information including OS, performance status (PS) and neurological status of the 12 pts who were alive at the cutoff of the previous study was updated in 2014. Results: The median follow-up period of all 23 pts was 41.6 months (range 0–143). The median OS and 5-year OS rate were 48.7 months and 49.7% (95% confidence interval 28–68%), respectively. Univariate analysis showed that better PS at diagnosis (0–2 vs. 3–4), age at diagnosis ( < 40 vs. ≥ 40 years), response to initial therapy (complete remission and partial remission vs. stable disease and progressive disease), and curative-intent whole brain radiotherapy (WBRT) ( ≥ 30 Gy vs. others) affected OS (p = 0.003, 0.03, < 0.001, < 0.001, respectively). Nine of the 12 pts who were alive at the previous study cutoff were alive in 2014. One patient died due to general prostration while keeping complete remission, and two were lost to follow-up. Among the 12 pts, no recurrence was documented. In terms of motor/cognitive function of the 9 living pts, 3 pts became worse and 3 improved compared with pre-treatment status, and 3 pts remained stable. None of the pts had leukoencephalopathy ≥ grade 3. Conclusions: Curative-intent WBRT and good PS at diagnosis were strong factors of favorable prognosis in AIDS-related PCNSL in the cART era. Our results suggest that WBRT with adequate cART for untreated AIDS-related PCNSL is an effective treatment modality. These findings should be confirmed in prospective studies.
SAT-083-Simple non-invasive surrogates of portal hypertension predict clinical decompensation in overweight/obses patientes with cACLD
Authors: Yuly Paulin Mendoza, Sila Cocciolillo, Giuseppe Murgia, Tianyan Chen, Cristina Margini, Giada Sebastiani, Annalisa Berzigotti
Journal: Journal of Hepatology (2019)
Abstract 19468: Overexpression of O-GlcNAcase in Coronary Endothelial Cells Improves Cardiac Contractility in Type 2 Diabetes
Authors: Rui Si, Rui Guo, Qian Zhang, Ayako Makino
Journal: Circulation (2017)

Ischemic heart disease is the leading cause of death in diabetic patients and coronary endothelial dysfunction plays a crucial role in the development and progression of ischemic heart disease. Excessive protein O-GlcNAcylation is observed in diabetic patients and it contributes to the functional changes in many tissues. To define the role of protein O-GlcNAcylation in coronary endothelial functions in diabetes, we used our unique transgenic mouse, endothelial cell (EC)-specific tet-inducible O-GlcNAcase (OGA, an enzyme which decreases protein O-GlcNAcylation) mouse and crossed it with TALLYHO mouse (TH mouse, a polygenic model for type 2 diabetes). TH mice exhibited increased apoptotic ECs and reduced capillary density in the left ventricular (LV) compared to the wild-type (WT) mice. Myocardial infarct size after ischemia/reperfusion was increased and cardiac functions were attenuated in TH mice compared to WT mice. Mouse coronary ECs (MCECs) isolated from TH mice showed higher protein O-GlcNAcylation th...
Clinicopathological features and prognostic analysis of extragastrointestinal stromal tumor in an Asian center.
Authors: Jing-yun Wen, Min Dong, Dan-yun Ruan, Dong-hao Wu, Ze-xiao Lin, XiangYuan Wu
Journal: Journal of Clinical Oncology (2015)

e21509 Background: Extragastrointestinal stromal tumor (EGIST) shows features of GIST outside the gastrointestinal tract, occurring mainly in the omentum, mesentery and retroperitonium. EGIST is rare, comprising only 5% to 10% of all GISTs. Few studies have been performed with a focus on EGIST. The aim of this study was to better define the clinicopathological features and prognostic factors of EGISTs. Methods: Data were collected from 20 patients with a histological diagnosis of EGIST were admitted to the third affiliated hospital of Sun Yat-Sen university from January 2003 to May 2014. We recorded the patients’ clinicopathological information including age, gender, tumor size, surgery type, capsular integrity, metastatic sites at diagnosis and tumor risk category by reviewing the medical records. Immunohistochemistry was performed for HSP90, CD117, CD34, DOG1, VEGF, Ki-67, desmin, SMA, S-100 protein. Univariate analyses were performed using the Kaplan-Meier method, a multivariate analysis were done by the Cox regression analysis. Results: Mean follow-up was 48 months. The median disease free survival time (DFS) was 28 months. The 1- and 2-year survival rates were 85% and 70% respectively. The EGISTs were positive for CD117 in 95 % (19/20), CD34 in 65% (11/20), DOG-1 in 75% (15/20), HSP-90 overexpression in 40%(8/20),HSP-90 low expression in 60%(12/20), desmin in 15%(3/20), SMA in 5%(1/20), S-100 in 25% (5/20) of samples. For Ki-67 labeling index (Ki-67 LI):30% were < 5%, 45% were between 5-10%, 25% were > 10%.Survival analysis indicated that mitotic counts, overexpression of HSP90 and Ki-67 index were significant predictors for survival. Conclusions: The results of this study show mitotic counts, overexpression of HSP90 and Ki-67 index may be useful for predicting the prognosis of EGIST.
PS-070-Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study
Authors: Heather Valerio, Maryam Alavi, David Silk, Carla Treloar, Andrew Milat, Adrian Dunlop, Jo Holden, Charles Henderson, Janaki Amin, Phillip Read, Louisa Degenhardt, Gregory Dore, Jason Grebely
Journal: Journal of Hepatology (2019)
A new IgE Western blot identifies <i>Aspergillus fumigatus</i> sensitization and may discriminate allergic bronchopulmonary aspergillosis
Authors: Raphaël Pierre Piarroux, Jean‐Christophe Dubus, Martine Reynaud‐Gaubert, Marion Gouitaa, Stéphane Ranque, Joana Vitte
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Abstract 15755: Adverse Cardiac Remodeling in Obese Children
Authors: Aparna Kulkarni, Jose Miguel Mateo D Lorenzo, Talin Gulesserian, Frederick Kaskel, Joseph Mahgerefteh
Journal: Circulation (2015)

Background: Obesity (OB) and hypertension (HTN) are risk factors for early cardiovascular disease (CVD). The aim of this study was to determine the effect of OB and HTN on myocardial mechanics in children using speckle-tracking echocardiography (STE). Methods: Echocardiograms (echo) and ambulatory blood pressure monitors were performed in children referred for HTN from 2009 to 2014. Traditional echo Doppler indices, mass and volume parameters, 24-hr systolic blood pressures (24SBP) and 24-hr diastolic BP indices were obtained. Post-processing was performed on the 2D gray scale images of LV in apical 4-chamber and parasternal short axis mid-papillary views to obtain strain indices (Image Arena, Tomtec). Associations of obesity and BP to the myocardial indices were explored independently using Spearman correlation coefficient. Results: Among 107 patients, 6 - 21 yrs age, 79.4% were males; 42% OB and 53% were hypertensive. Mean Z scores for BMI were 1.5 ± 1.1 and SBP were 1.5 ± 1.2. Mean LV mass (LVM, 2D area-length) was 131 + 42.8 gms, LVMI 2.7 was 40.7 + 9.6 gms, LVM/volume ratio was 0.94 + 0.17. Mean mitral septal E/e’ was 8.3 + 2.1, lateral E/e’ was 5.9 + 1.5 and mitral E/A ratio was 1.8 + 0.4. The mean global longitudinal strain (GLS) was – 17.7 + 3.6, global circumferential strain (GCS) was -20.4 + 3.8, average radial strain (ARS) was 22 + 11.9, average longitudinal strain rate (ALSR) was -1.0 + 0.35 and average circumferential strain rate (ACSR) was -1.5 + 0.5 for all patients. BMI Z scores positively correlated with LVM (r=0.38, p&lt;0.01), LVM/vol (r=0.32, p&lt;0.01), mitral E/e’ (r=0.28, p&lt;0.01), LVMI 2.7 (r=0.5, &lt;0.01). Increased BMI negatively correlated to GLS, GCS and ACSR (r=0.3, p&lt;0.01). Higher SBP, diastolic and mean BP were associated with higher mitral medial E/e’ (r=0.3, p&lt;0.01), however did not have statistically significant correlations to strain indices. Conclusions: Obesity causes adverse cardiac remodeling in obese children. This may provide insights into mechanisms of long-term CV effects of obesity. Myocardial effects of HTN were not apparent, possibly due to heterogeneity of the study group and low power.
FRI-376-Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival
Authors: Federica Invernizzi, Massimo Iavarone, Claudio Zavaglia, Stefano Mazza, Umberto Maggi, lucia cesarini, Barbara Antonelli, Aldo Airoldi, Matteo Angelo Manini, Angelo Sangiovanni, Giorgio Rossi, Maria Francesca Donato, Luca Saverio Belli, Pietro Lampertico
Journal: Journal of Hepatology (2019)
Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative
Authors: M.A.S. Soares, L. Antunes, P. Redondo, M. Borges, R. Hermans, D. Patel, F. Grimson, R. Munro, C. Chaib, L. Lacoin, M. Daumont, J.R. Penrod, J.C. O’Donnell, M.J. Bento, F.R. Goncalves
Journal: Annals of Oncology (2019)

Background: Understanding Tx patterns and related outcomes in the rapidly changing NSCLC landscape informs clinical decision-making. As part of I-O Optimise, a multinational research platform providing real-world insights into the management of lung cancers, Tx patterns and OS are reported for pts with NSCLC prior to immunotherapy reimbursement in Portugal.
THU-116-Effectiveness of the salvage therapy sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) in chronic hepatitis C: Clinical practice experience from the TRIO Network
Authors: Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, Nezam Afdhal
Journal: Journal of Hepatology (2019)
FRI-048-Faecal calprotectin in PSC-IBD is a prognostic marker of cholangitis associated complications
Authors: Polychronis Pavlidis, Yasser El-Sherif, Ben Warner, Shraddha Gulati, Konstantinos Sarras, Ellie Alberts, Joe Segal, Tamir Rashid, Phil Harrison, John Devlin, Gwion Emlyn, Hadil Abu Arqoub, Patrick Dubois, Alberto Sanchez-Fueyo, Michael Heneghan, Deepak Joshi, Nick Powell, Bu Hayee
Journal: Journal of Hepatology (2019)
THU-146-LDV/SOF/RBV is an effective first-line DAA regimen as well as retreatment option for RF1_2k/1b patients within Georgian national hepatitis C elimination program
Authors: Marika Karchava, Nikoloz Chkhartishvili, Lali Sharvadze, Akaki Abutidze, Natia Dvali, Lana Gatserelia, Lela Dzigua, Natalia Bolokadze, Adam Kotorashvili, Paata Imnadze, Amiran Gamkrelidze, Tengiz Tsertsvadze
Journal: Journal of Hepatology (2019)
Vemurafenib to eliminate BRAF-mutated circulating epithelial tumor cells (CETCs) from blood of patients with malignant melanoma.
Authors: Dorothea Zimon, Monika Pizon, Ernst-Ludwig Stein, Ulrich A. Pachmann, Katharina Pachmann
Journal: Journal of Clinical Oncology (2015)

11031 Background: Almost 50% of melanomas harbor mutations in BRAF, mainly V600E. The mutations are usually identified in the primary tumor. However, the primary tumor is often no longer available and metastases not always reflect the characteristics of the primary tumor. In melanoma it is not clear at what stage epithelial antigen is expressed. CETCs are present in peripheral blood in a significant proportion of patients with malignant melanoma. The aim of the present study was to analyze whether these cells belong to melanoma clone due to the presence of the BRAF gene mutation in these cells. For this reason, the analysis of multiple isolated CETCs from individual patients for BRAF gene mutations was performed. Methods: Blood from patients with malignant melanoma was analyzed for cells positive for the EpCAM and Melan-A using the maintrac approach, avoiding cell selection and using an image analysis system for detection. Subsequently, between 8-20 EpCAM and Melan-A positive cells from each patient were isolated individually using a semi-automated capillary approach and deposited one by one into micro cups. The DNA of individual cells was amplified by whole genome amplification and assayed using the cobas BRAF V600 mutation test. Furthermore, we performed mutation analysis of cells after magnetic bead enrichment which is known to contain a mixture of CETCs and leukocytes. Results: DNA could be amplified from all individually isolated cells. In addition, we analyzed the presence of V600 mutation after magnetic bead enrichment. A BRAF mutation was detected in 20 - 75 % of evaluable cells in patients with BRAF mutation in primary tumor. In advanced stage or metastatic patients under Vemurafenib therapy, we were not able to find mutated CETCs. Conclusions: Individually isolated CETCs from the peripheral blood from patients with melanoma allow not only to detect mutations but also to determine the frequency of mutated cells. This proves that at least part of the CETCs is originated from the primary tumor. Furthermore, detection of BRAF mutation in CETCs may be crucial for a successful molecular-targeted therapy.
FRI-390-Management of dyslipidemia after liver transplantation
Authors: Samarth Patel, Viviana Rodriguez, Mohammad Bilal Siddiqui, Fei-Pi Lin, Masoud Faridnia, Joseph Clinton, John Laurenzano, Anchalia Chandrakumaran, Trevor Reichman, Chandra Bhati, Mohammad Siddiqui
Journal: Journal of Hepatology (2019)
Durable remissions with Ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts): Results of a South African Expanded Access Program (EAP).
Authors: Daniel A. Vorobiof, Bernardo Leon Rapoport, Lydia Mary Dreosti, Adam L. Nosworthy, Georgina Laird McAdam, Johann Petrus Jordaan, Bonnie M. K. Donato, Lara Qatami, Hennie Duvenhage, Tienie Stander, Margreet Bergh, Janetta De Beer
Journal: Journal of Clinical Oncology (2015)

e20112 Background: This retrospective analysis reports data on demographics and outcomes of an ipilimumab South African EAP. Ipilimumab was given at a dose of 3 mg/kg intravenously every 3 weeks for 4 cycles to adults with MMM who failed at least 1 line of treatment for metastatic disease. The primary objective was overall survival (OS). Methods: Data were collected from 23 participating institutions, with 248 pts. Available data on 119 pts is reported. All patients signed an informed consent. Results: Of the 119 pts, 88 (74%) had cutaneous melanoma and 31 patients (26%) had non cutaneous melanoma, including uveal, mucosal, and MMM of unknown primary. Twenty pts previously received two or more lines of treatment for MMM. The median age was 59 years (range 27 – 86) and there were 82 (69%) males and 37 (31%) females. Baseline ECOG PS was 0 in 35%, PS 1 in 58% and PS 2 in 7% of pts. LDH was normal in 47 pts (39%), 22 (18%) had a LDH > ULN and unknown in 50 (42%). Site of metastasis included brain in 21 pts (18%) and liver in 34 (29%). Ten pts received re-induction treatment according to protocol. The median OS was 8.89 months (274 days) [95% CI, 7.47 – 10.79]; 1-year survival was 36%, 2-year survival was 20%, 3-year survival was 20%. The survival without progression at 1 year was 22%, 2-year survival was 14% and 3-year survival was 12%.The longest recorded survival was 3.4 years. No independent prognostic variables were identified to predict for 1- and 2-year survival by univariate analysis and multivariate Cox proportional hazard model. Toxicities were similar as those previously reported for ipilimumab. Conclusions: Ipilimumab is an effective treatment option for pts with pretreated MMM. Ipilimumab can induce durable disease control and long-term survival.
Effects of hypothalamic radiation therapy exposure on cardiometabolic risk factors and bone density in survivors of childhood brain tumors.
Authors: Susan Wu, Raven Melissa Cooksey, Gloria Vega, Laura J. Klesse, Daniel C. Bowers
Journal: Journal of Clinical Oncology (2015)

e21028 Background: Although obesity is well described following cranial radiation exposure, the prevalence of and risk factors for metabolic syndrome and bone density among childhood brain tumor survivors exposed to hypothalamic radiation therapy are not well described. Methods: Patients underwent fasting lab assays (lipid panel, insulin, glucose, leptin, and adiponectin), anthropometric measurements (height, weight, waist circumference), and body composition by Dual-energy X-ray Absorptiometry (DXA). Insulin resistance was identified using the homeostasis model assessment of insulin resistance (HOMA-IR). Metabolic syndrome was diagnosed according to the International Diabetes Foundation criteria in children 10 years and older; children between 5-10 years of age who met 3/5 risk factors were classified as having concomitant cardiometabolic risk. Results: 145 survivors of childhood brain tumors (70 exposed to hypothalamic radiation; 75 not exposed) between 5-21 years old (mean age: 13.5 years, SD: 3.9 years, mean interval since treatment: 72 months) were examined. Metabolic syndrome and/ or metabolic risk factors were more common in patients who were exposed to hypothalamic radiation (7/38, 18.4%) than those who were not exposed (4/76, 5.2%) (p = 0.04). Patients exposed to hypothalamic radiation had lower Bone Mineral Content (BMC) and Bone Mineral Density (BMD) z-scores (-1.3 vs. -0.3; p = 0.003 and -1.4 vs. -0.2; p = < 0.001 respectively). Patients who were exposed to hypothalamic radiation were more likely to have elevated triglyceride levels (p = 0.02), low HDL levels (p = 0.04), and lower IGF-1 levels (p = 0.001). Patients with elevated HOMA-IR had elevated leptin levels (p = 0.001), lower adiponectin levels (p = 0.04), and elevated leptin:adiponectin ratios (p = 0.001). Conclusions: These results demonstrates that childhood brain tumor survivors who have been exposed to hypothalamic radiation are at increased risk of developing components of metabolic syndrome, in particular dyslipidemia and insulin resistance, as well as decreased bone density. These findings have significant clinical implications for the long-term care of these patients.
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Authors: Masataka Takenaka, Martin Köbel, Dale W. Garsed, Sian Fereday, Ahwan Pandey, Dariush Etemadmoghadam, Joy Hendley, Ayako Kawabata, Daito Noguchi, Nozomu Yanaihara, Hiroyuki Takahashi, Takako Kiyokawa, Masahiro Ikegami, Hirokuni Takano, Seiji Isonishi, Kazuhiko Ochiai, Nadia Traficante, Sreeja Gadipally, Timothy Semple, Dane Vassiliadis, Kausyalya Amarasinghe, Jason Li, Gisela Mir Arnau, Aikou Okamoto, Michael Friedlander, David D. L. Bowtell
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcomes are observed in a subset of patients. The explanation for this is unknown but may be due to misclassification of high-grade serous ovarian cancer (HGSOC) as OCCC or mixed histology. Experimental Design: To discover potential biomarkers of survival benefit following platinum-based chemotherapy, we ascertained a cohort of 68 Japanese and Australian patients in whom progression-free survival (PFS) and overall survival (OS) could be assessed. We performed IHC reclassification of tumors, and targeted sequencing and immunohistochemistry of known driver genes. Exome sequencing was performed in 10 patients who had either unusually long survival (N = 5) or had a very short time to progression (N = 5). Results: The majority of mixed OCCC (N = 6, 85.7%) and a small proportion of pure OCCC (N = 3, 4.9%) were reclassified as likely HGSOC. However, the PFS and OS of patients with misclassified samples were similar to that of patients with pathologically validated OCCC. Absent HNF1B expression was significantly correlated with longer PFS and OS (P = 0.0194 and 0.0395, respectively). Mutations in ARID1A, PIK3CA, PPP2R1A, and TP53 were frequent, but did not explain length of PFS and OS. An exploratory exome analysis of patients with favorable and unfavorable outcomes did not identify novel outcome-associated driver mutations. Conclusions: Survival benefit following chemotherapy in OCCC was not associated with pathological misclassification of tumor histotype. HNF1B loss may help identify the subset of patients with OCCC with a more favorable outcome.
SAT-293-Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD
Authors: Peter Eddowes, Michael Allison, Emmanouil Tsochatzis, Quentin Anstee, David Sheridan, Indra Neil Guha, Jeremy Cobbold, Valérie Paradis, Pierre Bedossa Philip Newsome
Journal: Journal of Hepatology (2019)
Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma
Authors: Emily Stamell Ruiz, Pritesh S. Karia, Robert Besaw, Chrysalyne D. Schmults
Journal: JAMA Dermatology (2019)

Brigham and Women's tumor classification (BWH) better predicts poor outcomes than American Joint Committee on Cancer (AJCC) 7th edition (AJCC 7). AJCC 8th edition (AJCC 8) has not been evaluated.